From the impact of Obamacare to cutting edge research, from biotech buyouts to big pharma court battles, the Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week's edition, the team talks about big pharma patent disputes, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.